Arrowhead rises as it begins trial of high-cholesterol disorder drug

Shares of Arrowhead Pharmaceuticals rise 2% to $67.95

California-based drugmaker says it has begun testing its experimental drug ARO-DIMER-PA for mixed hyperlipidemia, a disorder marked by high levels of cholesterol and blood fat

The drug is designed to silence two genes at once to lower LDL, or "bad" cholesterol, and triglycerides – both linked to heart disease, per co

Co says the early-stage study will enroll up to 78 adults to assess safety and efficacy

In earlier animal studies, the drug sharply reduced cholesterol and triglycerides, co say

Shares up ~253% in 2025